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The reversal rate from clustering of cardiovascular disease (CVD) risk factors—components of the metabolic syndrome (MetS)
is not known. Methods and Results. Among 35,534 subjects who received the annual health examinations at the NiigataHealth
Foundation (Niigata, Japan), 4,911 subjects had clustering of 3 or more of the following CVD risk factors: (1) body mass index
(BMI) ≥25Kg/m2, (2) blood pressure ≥130mm Hg in systolic and/or ≥85mm Hg in diastolic, (3) triglycerides ≥150mg/dL, (4)
high-density lipoprotein cholesterol ≤40mg/dL in men, ≤50mg/dL in women, and (5) fasting blood glucose ≥100mg/dL. After
5 years 1,929 subjects had a reversal of clustering (39.4%). A reversal occurred more often in males. The subjects with a reversal of
clustering had milder level of each risk factor and a smaller number of risk factors, while BMI was associated with the least chance
of a reversal. Conclusion. We concluded that a reversal of clustering CVD risk factors is possible in 4/10 subjects over a 5-year
period by habitual or medical interventions. Gender and each CVD risk factor aﬀected the reversal rate adversely, and BMI was
associated with the least chance of a reversal.
1.Introduction
Metabolic syndrome (MetS) is diagnosed as a clustering
of cardiovascular disease (CVD) risk factors, including
obesity, hypertension, impaired glucose metabolism, and
dyslipidemia, and the diagnostic criteria have been proposed
by several organizations [1–5]. MetS or clustering of CVD
risk factors is apparently a risk for new onset of diabetes
mellitus [6], kidney dysfunction [7], cardiovascular diseases,
and increased mortality [8–12].
The components of MetS, namely, the CVD risk factors,
have been shown to actually cluster more frequently than
to occur by chance, and the actual prevalence of clustering
exceeded the predicted one by 1.3, 3.0 and 8.0 for 3, 4, and 5
clustering of CVD risk factors [13].
For such clustering of CVD risk factors in MetS, insulin
resistance was initially believed to play a key role [14], but
the roles of adipocytokines released from visceral adipose
tissue have been increasingly emphasized [15, 16], and waist
circumferencehas become essential forthe diagnosis of MetS
[1–4]. Furthermore, both inﬂammation [17] and oxidative
stress [18] have been implicated in the pathogenesis of MetS.
In our previous study [19], new onset of MetS was deter-
minedasnewclusteringof3ormoreCVDriskfactorsduring
the followup of 5 years in the general population. In this
study, we studied the reversal rate from clustering of CVD
riskfactorsduringthesamefollowupperiod.Therateofnew
clustering and its reversal would give us a clue to estimate the
dynamic aspects of clustering or MetS. The role of each CVD
risk factor on clustering and its reversal were also evaluated.2 Journal of Obesity
2. Methods
2.1. Study Subjects. This community-based, observational
cohort study was based on data of annual health exami-
nations at the Niigata Health Foundation (Niigata, Japan).
The examination is supported by the local government, is
available to residents over 20 years of age, and is especially
recommended for those without current medication. The
examination consists of a detailed medical history: physical
examination, blood examination including blood cell count
and biochemical markers, chest X-ray, and a 12-lead ECG.
This report included 35,534 subjects who received the
examination both in 1996 as the baseline examination and
5y e a r sl a t e r .
2.2. Deﬁnition of Clustering. B e c a u s eo fal a c ko fd a t ao f
waistcircumference,wedeﬁnedclusteringwhensubjectshad
at least 3 of the following CVD risk factors: (1) elevated
body mass index (BMI) ≥25Kg/m2, (2) elevated systolic
(≥130mm Hg) and/or diastolic blood pressure (≥85mm
Hg), (3) elevated triglycerides (≥150mg/dL), (4) low high-
density lipoprotein (HDL) cholesterol (≤40mg/dL in men,
≤50mg/dL in women), and (5) elevated fasting blood
glucose (FBG) ≥100mg/dL. The subjects who were under
therapy for hypertension, diabetes mellitus, and high TG
were considered to have these items.
BMI was calculated by dividing the body weight in
kilograms by the square of the height in meters, and this
was used instead of waist circumference which was not
available in our database at that time. Because of the dif-
ferences in BMI between Japanese and Western populations,
values ≥25kg/m2 were considered elevated in contrast to
≥30kg/m2 as in Western populations according to criteria of
the Japan Society for the Study of Obesity [20–22].
2.3. Data Analysis. The baseline characteristics between the
subjects who had clustering of CVD risk factors versus
nonclustering was compared. Then, the reversal rates of
clustering to 2 or less CVD risk factors were determined. The
risk of age, gender, each CVD risk factor, and the number of
clustered CVD risk factors regarding the reversal rate were
determined.
Comparisons were undertaken by the unpaired t-test for
continuous variables which were expressed as mean ± SD
and the X2 test for categorical variables. Hazard ratios and
95% CIs were calculated from the Cox proportional-hazard
m o d e l s .C o xm o d e l sw e r ea d j u s t e df o ra g ea sac o n t i n u o u s
value and for sex to evaluate the contribution of each CVD
risk factor and their combinations in the baseline data. All
statistical analyses were performed with SPSS, version 12.0
(SPSS Inc, Chicago, Ill).
Two-sided values of P at .05 were considered statistically
signiﬁcant. The authors had full access to and take full
responsibility for the integrity of the data. All authors have
read and approved the manuscript as written.
3. Results
3.1. Baseline Characteristics of Study Subjects. The baseline
characteristics of the subjects are shown in Table 1.T h e
mean age was 59.4 ± 10.0 years, and 67.9% of the subjects
were women. The prevalence of each CVD risk factor, item
of MetS, was 20.6%, 53.1%, 12.6%, 18.7%, and 21.1% for
obesity, elevated blood pressure, low HDL cholesterol, high
TG, and abnormal FBG, respectively. Clinical hypertension
(≥140mm Hg in systolic and/or ≥90 mm Hg in diastolic)
was present in 20% and antihypertensive treatment was
administered to 14.0%. Diabetes was found in 12%, and
2.4% were under treatment. Clustering of CVD risk factors
was present in 4,911 subjects (13.8%) who were older
(P< . 001) and had elevated BMI, blood pressure, TG
and FBG and decreased HDL compared to those without
clustering (Table 1).
3.2. Reversal Rate of Clustering. During the follow-up of
exactly 5 years, 1,929 subjects among 4,911 subjects who had
clustering of CVD risk factors at the baseline study no longer
had clustering, and the reversal rate was found in 39.4%.
The reversal rate of each CVD risk factoring was 41.0%,
30.4%, 65.2%, 37.1%, and 37.1% for BMI, blood pressure,
TG, FBG, and HDL, respectively, in the subjects with a
reversal, while in those without a reversal, a reversal was
found only in HDL (15.2%) and TG (0.9%). Concerning
other items, there was a tendency towards an increase by
0.6%, 0.7%, and 16.7% for BMI, blood pressure, and FBG
levels, respectively.
3.3. Predictors of Reversal of Clustering of CVD Risk Factors.
At the baseline study, obesity, elevated blood pressure, and
FBG were found less often in the subjects with a reversal
of clustering of CVD risk factors in comparison with those
without a reversal: 58.2% versus 73.9% (P<. 001), 89.5%
versus 91.4% (P<. 03), and 54.8% versus 59.1% (P<. 03),
respectively, and others were comparable (Table 2).
A reversal of clustering was found more often in males
than females: 42.3% versus 37.5% (hazard ratio = 1.31, 1.15–
1.50), but age dependency was not observed. Among CVD
risk factors, obesity (BMI ≥25kg/m2) was associated with
the least likelihood of reversal of clustering compared with
the others (hazard ratio = 0.275 for BMI versus 0.411, 0.483,
0.416, and 0.515 for elevated blood pressure, triglycerides,
FBG, and reduced HDL cholesterol, resp.) (Table 3).
In the subjects with a reversal of clustering, 3, 4, and 5
risk factors were found in 84.0%, 14.9%, and 1.1% while in
those without a reversal, they were found in 66.8%, 27.4%,
and 5.8%, respectively, and these diﬀerences were signiﬁcant
(P<. 001). Fewer numbers of risk factors were found in the
subjects with a reversal (Table 2). As the number of the risk
factors increased, the reversal rate of clustering of CVD risk
factors declined from 44.8% for 3, 26.0% for 4, and 12.8%
for 5 CVD risk factors, and the hazard ratio for a reversal
decreased (Table 3).
4. Discussion
Atthebaselinestudy,4,911persons(13.8%)hadclusteringof
CVD risk factors ≥3, and at the followup 5 years later, 1,929
no longer had clustering and the reversal rate was 39.4%.Journal of Obesity 3
Table 1: Baseline characteristics of subjects with (≥3) and without clustering (0–2) of CVD risk factors.
All subjects (n = 35,534) Without clustering (n = 30,623) With clustering (n = 4,911)
Male (%) 32.1 32.2 32.1
Age (years) 59.4 ±10.05 9 .1 ±10.06 1 .7 ±9.0
∗
BMI (≥25kg/m2)2 2 .8 ±2.92 2 .4 ±2.62 5 .7 ±2.8
∗
Blood pressure (mmHg)
Systolic (≥130mmHg) 128.7 ±17.3 126.9 ±16.9 140.5 ±14.9
∗
Diastolic (≥85mmHg) 77.4 ±10.77 6 .4 ±10.58 3 .3 ±9.8
∗
HDL cholesterol (mg/dl)
Men (≤40mg/dL) 60.4 ±15.26 2 .3 ±5.54 9 .9 ±13.8
∗
Women (≤50mg/dL) 64.9 ±14.66 6 .6 ±14.55 1 .5 ±13.0
∗
Triglyceride (≥150mg/dl) 100.8 ±65.89 0 .1 ±48.0 167.7 ±108.6
∗
FBG (≥100mg/dL) 93.2 ±14.09 1 .7 ±12.1 102.9 ±19.7
∗
BMI: Body mass index. HDL cholesterol: High-density lipoprotein cholesterol. FBG: Fasting blood glucose.
Table 2: Comparisons of basal characteristics between the entire subjects and those with and without reversal of clustering of CVD risk
factors.
Characteristics All 4911 With reversal (n = 1929) No reversal (n = 2982) P value
Risk factor (%)
Obesity 67.7 58.2 73.9 <.001
Elevated blood pressure 90.7 89.5 91.4 .03
Low HDL cholesterol 47.9 47.2 48.4 .413
Elevated triglycerides 66.6 67.3 66.1 .369
Impaired glucose tolerance 57.4 54.8 59.1 .003
Number of risk factors
3 73.6 84.0 66.8 <.001
4 22.5 14.9 27.4 <.001
5 4.0 1.1 5.8 <.001
Table 3: Multivariate analysis of hazard risks concerning reverse
clustering of CVD risk factors after 5 years.
Risk factor HR (95% CI) P value
Risk factor
Obesity 0.275 (0.233–0.323) <.001
Elevated blood pressure 0.411 (0.328–0.516) <.001
Low HDL cholesterol 0.515 (0.439–0.603) <.001
Elevated triglycerides 0.483 (0.41–0.569) <.001
Impaired glucose tolerance 0.416 (0.353–0.489) <.001
HR: Hazard ratio.
The subjects with a reversal of clustering had lower BMI,
lower blood pressure, lower TG, and lower FBG (P<. 001).
Higher HDL was associated with a reversal only in women
(P<. 006). As the number of CVD risk factors increased, the
reversal became less likely and BMI was the least associated
with a reversal.
For the diagnosis of MetS, many types of criteria have
been proposed from several organizations [1–5]. Waist
circumference has been used in most criteria except for that
of the American Association of Clinical Endocrinologists
(AACE) which is using BMI for the diagnosis of obesity [5].
Usingthesecriteria,theprevalenceofMetShasbeenreported
in many studies, but the incidence or reversal of MetS has
been scarcely reported.
In the Framingham Study, multimarkers were evaluated
to investigate their eﬀects on the incidence of MetS. Two
hundred eighty-two of 1,473 participants without prevalent
MetS at baseline developed MetS during the mean followup
of2.9years,andtheincidencewas6.6%/year[23].Inanother
study, 75 of 184 hypertensive patients (41%) initially free of
MetS at baseline subsequently fulﬁlled the criteria for MetS
duringthe4yearsoffollowup[24].AhighercalculatedCHD
risk (P<. 001) was found in those who developed MetS
compared with those who did not.
P r e v i o u s l y ,w er e p o r t e dt h a tM e t Sd e v e l o p e dn e w l yi n
9.32% during the 5 year followup period in the general
population [19] where MetS was diagnosed based on the
BMI but not on waist circumference. Of note, obesity (BMI
≥25Kg/m2) was associated with the highest hazard ratio in
developing MetS or more clustering of CVD risk factors than
other risk factors [19]. The importance of BMI would be
compatible with the results of Fox et al. [25] who showed
an association of obesity with newly developing MetS [25].
Furthermore, the present study showed that the reversal of
once diagnosed clustering of CVD risk factors ≥3o c c u r s
frequently, 39.4%, 5 years later, and BMI was associated with
the least likelihood of reversal of clustering of CVD risk4 Journal of Obesity
factors. For the reversal of clustering to occur, several factors
must be included.
In the medical examination in the general population,
thesubjectsaretoldtheabnormalﬁndingsifanyandadvised
to correct them. This is because early detection and the
correction of abnormal ﬁndings are the main purpose of
such an examination. Abnormalities may be corrected by
self-control or by medical intervention, and this will partly
explain the high reversal rate of clustering of CVD risk
factors. Compared to other CVD risk factors, BMI would be
diﬃcult to treat by drugs, and, hence, it might be the least
likely to be reversed.
Sampling variations or measurement errors may be
another factor and may be mistaken as the reversal of
clustering of CVD risk factors. These factors will aﬀect
both genders equally, but the reversal rate of clustering
was diﬀerent between men and women, suggesting that the
reversalwasnot duetoerrorsofsamplings ormeasurements.
Together with our previous study which revealed that 9.32%
of subjects without clustering at the baseline developed new
clustering of ≥3 CVD risk factors within 5 years [19], the
prevalence will continue to increase in spite of the reversal of
clustering by 39.4% from 13.8 to 16.4% after 5 years.
5. Limitations
We had some limitations in this study. First, this is a
retrospective observational study and analysis was relatively
limited. Next, we used BMI (≥25Kg/m2) as the criterion of
obesity. BMI reﬂects both visceral and subcutaneous obesity,
and visceral obesity might be undetected by BMI. Clustering
of ≥3 risk factors as deﬁned in the present study must be
an approximation of the MetS which is deﬁned using waist
circumference [1–4]. However, BMI has been shown to play
a role in developing new onset of atrial ﬁbrillation [19]a n d
chronic kidney disease [26] in addition to clustering of risk
factors. Another limitation might be the fact that all subjects
did not receive the same intervention in CVD risk factors but
suchwouldbenotpossibleinthiskindofapopulation-based
study.
6. Conclusion
In conclusion, 39.4% of subjects with clustering of 3 or more
CVD risk factors at the baseline study showed a reversal
during the 5 years of followup. The reversal occurred more
often in males, and the subjects with a reversal of clustering
had milder levels of each risk factor and a smaller number
of risk factors. Each risk factor aﬀected the reversal, but BMI
was associated with the least likelihood of a reversal.
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